Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vi-Siblin for low anterior resection syndrome after rectal cancer surgery
2024-514541-11-00Phase 2Authorised
- Sponsor
- Sykehuset Telemark
- Start
- Apr 2026
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in low anterior resection syndrome (LARS) comparing Vi-Siblin with Placebo (2 arms). Primary endpoint: Total LARS score. Planned start Apr 2026; status: authorised.
02
Drugs
psyllium husks
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on 2024-514541-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514541-11-00.